Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

NCT02220309 | Completed DMC FDA Drug

• 1 other identifier: 27937
• Study Type: observational
• Target: 167
• Locations: 1 country
• Sites: 3

Brief Summary

This research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. Our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning. This study has recently added an additional treatment component: participants undergo a 12 week course of either Pramipexole medication or rTMS therapy (explained below). The ultimate goal of the study is to offer participants experiencing anxiety and depression a treatment that is alternative to ones that have failed them in the past, and to apply the knowledge we gain from investigating the brain circuits involved in anxiety and depression to help personalize treatments. We invite anyone who has recently experienced any symptoms of anxiety and/or depression to participate (no diagnosis is required to participate).

Conditions

Anxiety; Depression

Keywords

Anxiety; Depression; Social Anxiety Disorder; Bipolar disorder II; PTSD; GAD; Phobia

Outcome Measures

Primary Outcomes (3)

• Assessments of symptoms and daily functioning

  General demographics questionnaires, alcohol use questionnaire, substance use questionnaires, Mood and Anxiety Symptom Questionnaire, Penn State Worry Questionnaire, Health at Work Performance Questionnaire, WHO Quality of Life questionnaire, Satisfaction with Life Survey, Emotion Regulation Questionnaire, Brief COPE questionnaire, Early Life Stress questionnaire, Quick Inventory of Depressive Symptomatology, Beck Depression Inventory, PTSD Checklist - Civilian Version, Beck Anxiety Inventory, Barratt Impulsiveness Scale, MINI Neuropsychiatric Interview

  12 weeks

• Brain imaging

  Non-invasive MRI brain scan to see function and structure of brain.

  12 weeks

• Cognitive assessment

  WebNeuro is an objective assessment of cognitive strengths and weaknesses. It provides an accurate and objective assessment of person's cognitive function and efficiency.

  12 weeks

Study Arms (1)

Anxiety and mood disorders

Drug: Pramipexole Oral Tablet

Interventions

Pramipexole Oral Tablet DRUG

Pramipexole is an oral Dopamine agonist.

Anxiety and mood disorders

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

We expect to enroll 160 individuals spanning the spectrum of anxiety and associated mood symptoms. These individuals include patients of the Gronowski Center, a community clinical psychology center in Palo Alto. We will also recruit from the community through various advertisements. Further, participants will include healthy people recruited by advertisement.

You may qualify if:

• Recent experiences of anxiety and/or depression
• Ages 18-65

You may not qualify if:

• Specific psychiatric medications (case-by-case basis)
• A diagnosis of Bipolar 1 Disorder, Schizophrenia, or Obsessive Compulsive Disorder
• Any of the following medical conditions: Parkinson's disease; liver or kidney disease; history of epilepsy or seizures; history of cardiovascular disorders (specifically orthostatic hypotension)

Sponsors & Collaborators

• Stanford University: lead

Study Sites (3)

Gronowski Center-5150 El Camino Real

Los Altos, California, 94022, United States

Location

VAPAHCS/Palo Alto MIRECC-3801 Miranda Avenue

Palo Alto, California, 94304, United States

Location

Stanford University Department of Psychiatry

Stanford, California, 94305, United States

Location

Related Publications (1)

• Williams LM, Goldstein-Piekarski AN, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O'Hara R, Schatzberg AF, Suppes T, Yesavage J. Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. BMC Psychiatry. 2016 Mar 15;16:68. doi: 10.1186/s12888-016-0771-3.

  PMID: 26980207 DERIVED

Related Links

• Research on Anxiety and Depression: The RAD Project
• Research on Anxiety and Depression: The RAD Project

Biospecimen

Retention: NONE RETAINED

We will collect saliva samples, and in exploratory analysis focus on consideration of genes associated with neuroimaging-behavior constructs.

MeSH Terms

Conditions

Anxiety Disorders; Depression; Phobia, Social; Bipolar Disorder; Stress Disorders, Post-Traumatic; Phobic Disorders

Interventions

Pramipexole

Condition Hierarchy (Ancestors)

Mental Disorders; Behavioral Symptoms; Behavior; Bipolar and Related Disorders; Mood Disorders; Stress Disorders, Traumatic; Trauma and Stressor Related Disorders

Intervention Hierarchy (Ancestors)

Benzothiazoles; Thiazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Leanne M Williams, PhD

  Stanford University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 13, 2014
• First Posted: August 19, 2014
• Study Start: August 11, 2013
• Primary Completion: December 18, 2024
• Study Completion: April 2, 2025
• Last Updated: January 5, 2026

Record last verified: 2025-12

Locations

US (3)